Study Finds Variability in ctDNA Detectability Across Seven Body Fluids in Metastatic Breast Cancer

A recent study published in *Nature Communications* has examined the detectability of circulating tumor DNA (ctDNA) across seven different body fluids in patients with metastatic breast cancer. The research provides new insights into how ctDNA, a biomarker used for minimally invasive tumor characterization, varies in its presence and representativeness depending on the fluid sampled. This study contributes to ongoing advancements in liquid biopsy technology, which has become an important tool in oncology.

The investigation analyzed ctDNA from blood, cerebrospinal fluid, saliva, urine, pleural effusion, ascites, and peritoneal lavage collected from patients with metastatic breast cancer. Researchers assessed the detectability of ctDNA in each fluid and compared its ability to reflect tumor-specific genetic alterations. The findings highlight significant differences among the fluids regarding their capacity to provide accurate molecular information about tumors. These results may have implications for optimizing liquid biopsy approaches based on specific clinical scenarios or disease sites.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 2, 2025

Related posts:

Verve Therapeutics Therapy Shows Competitive Efficacy, No Major Safety Concerns in Early Data, Analysts Report Biotechnology Companies Develop Protein-Degrading Drugs to Target Undruggable Proteins Over 15 Years Study Finds Southern Outdoor Workers in Agriculture and Construction Face Highest Heat Exposure Risks Study Compares Craniotomy and Endoscopic Surgery Outcomes for Recurrent Craniopharyngioma Treatment

Author

GOAI